Guidelines for gynecological cancer—an audit of current network documents in England and Wales. Issue 2 (1st March 2006)

• Record Type: Journal Article
• Authors: Leeson, S. C.; Edmondson, R. J.; Heatley, M. K.; Nunns, D.; Rollason, T.; Reynolds, K.; Seddon, D.; Whitaker, R.; Kehoe, S.
• Is Part Of: International journal of gynecological cancer. Volume 16:Issue 2(2006)
• Page Start: 470
• Page End: 477
• Publication Date: 2006-03-01
• Subjects: gynecological malignancy -- practice guidelines; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200603000-00002
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : The objective of this study was to assess the adequacy of network cancer guidelines paying particular attention to referral criteria, referral routes, tumor diagnosis, staging, and suggested management and care pathways for ovarian and endometrial cancer. Guidelines from 15 regions in England and Wales were analyzed quantitatively and qualitatively as a prospective audit of predefined data items and subsequently agreed management recommendations. Details of unit and center clinicians were included in a minority of documents (2 to 5/15). Multidisciplinary team membership was not usually offered (6/15). Among the least reported data items were histopathology minimum dataset for endometrial cancer and an algorithm for management or summary and clinical symptoms and signs for both cancers. Among the most reported data items were hysteroscopy and ultrasound scanning for endometrial cancer and CA125 and chemotherapy for ovarian cancer. Qualitative analysis revealed differing criteria for the use of endometrial biopsy and radiotherapy in endometrial cancer, for lymphadenectomy and management of recurrent disease in ovarian cancer, and for referral pathways and the use of computed tomography/magnetic resonance (MR) scanning in the assessment of either disease. This study concludes that consideration should be given to the development of national guidelines or templates to ensure consistency of management for gynecological malignancy in England and Wales.